摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-fluoro-4-trifluoromethyl-phenyl)-acrylic acid | 262608-88-8

中文名称
——
中文别名
——
英文名称
3-(2-fluoro-4-trifluoromethyl-phenyl)-acrylic acid
英文别名
3-(2-fluoro-4-trifluoromethyl-phenyl)acrylic acid;3-(2-fluoro-4-trifluoromethylphenyl)acrylic acid;3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoic Acid
3-(2-fluoro-4-trifluoromethyl-phenyl)-acrylic acid化学式
CAS
262608-88-8
化学式
C10H6F4O2
mdl
——
分子量
234.15
InChiKey
HWBLGORXWYIISR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2916399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温下应存于干燥密封的容器中。

SDS

SDS:0629b8987cf70e6737e0af23829c635c
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(2-fluoro-4-trifluoromethyl-phenyl)-acrylic acid 在 palladium 10% on activated carbon 氢气 作用下, 以 甲醇 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 4.0h, 以77%的产率得到3-(2-fluoro-4-trifluoromethyl-phenyl)-propionic acid
    参考文献:
    名称:
    WO2008/26149
    摘要:
    公开号:
  • 作为产物:
    描述:
    丙二酸2-氟-4-(三氟甲基)苯甲醛 反应 3.0h, 以gave 3-(2-fluoro-4-trifluoromethyl-phenyl)-acrylic acid as a colorless solid (5.030 g; 82%)的产率得到3-(2-fluoro-4-trifluoromethyl-phenyl)-acrylic acid
    参考文献:
    名称:
    5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS
    摘要:
    本发明涉及公式(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物,其中R1、R2、R3和R4如描述中所述,以及其盐,特别是药学上可接受的盐,以及将这些化合物用作药物,特别是作为促进睡眠的药物。
    公开号:
    US20110105514A1
点击查看最新优质反应信息

文献信息

  • NOVEL THIOETHER DERIVATIVES
    申请人:Bossenmaier Birgit
    公开号:US20050267179A1
    公开(公告)日:2005-12-01
    Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    本发明的对象是式(I)的化合物及其药学上可接受的盐、对映体形式、二对映异构体和消旋体,上述化合物的制备,含有它们的药物组合物及其制造,以及上述化合物在控制或预防癌症等疾病中的应用。
  • Novel oxazoles, their manufacture and use as pharmaceutical agents
    申请人:Bossenmaier Birgit
    公开号:US20050038091A1
    公开(公告)日:2005-02-17
    The present invention relates to novel oxazoles of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    本发明涉及公式(I)的新型噁唑,其药学上可接受的盐,对映体形式,非对映异构体和外消旋体,上述化合物的制备,含有它们的药物以及它们的制造,以及上述化合物在控制或预防癌症等疾病中的应用。
  • 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    申请人:Aissaoui Hamed
    公开号:US20100029617A1
    公开(公告)日:2010-02-04
    The invention relates to 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives and their use as orexin receptor antagonists.
    该发明涉及1,4,5,6,7,8-六氢-1,2,5-三氮杂-蓝花烷衍生物及其作为脑下垂体前叶皮质激素受体拮抗剂的用途。
  • 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES
    申请人:Aissaoui Hamed
    公开号:US20100093740A1
    公开(公告)日:2010-04-15
    The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH 2 or O; R 1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R 2 represents (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 2-4 )alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR 5 R 6 or cyclopropyl; R 3 represents (C 1-4 )alkyl, (C 1-4 )alkoxy-methyl or halogen; R 4 represents (C 1-4 )alkyl; R 5 represents hydrogen or (C 1-4 )alkyl; and R 6 represents hydrogen or (C 1-4 )alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    本发明涉及公式(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物,其中X代表CH2或O; R1代表苯基,该基团独立地单取代、双取代或三取代,其中取代基独立地选自由(C1-4)烷基,(C1-4)烷氧基,卤素,氰基,三氟甲氧基和三氟甲基的群组; R2代表(C1-4)烷基,(C1-4)烷氧基,(C2-4)烯基,卤素,氰基,羟甲基,三氟甲基,C(O)NR5R6或环丙基; R3代表(C1-4)烷基,(C1-4)烷氧甲基或卤素; R4代表(C1-4)烷基; R5代表氢或(C1-4)烷基; R6代表氢或(C1-4)烷基。本发明还涉及这种化合物的药学上可接受的盐;以及将这种化合物用作药物的用途;特别是作为促进睡眠激素受体拮抗剂。
  • 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:US08188082B2
    公开(公告)日:2012-05-29
    The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    本发明涉及一种式为(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物,其中X代表CH2或O;R1代表苯基,该基团独立地单取代、双取代或三取代,其中取代基独立地选自(C1-4)烷基,(C1-4)烷氧基,卤素,氰基,三氟甲氧基和三氟甲基的群;R2代表(C1-4)烷基,(C1-4)烷氧基,(C2-4)烯基,卤素,氰基,羟甲基,三氟甲基,C(O)NR5R6或环丙基;R3代表(C1-4)烷基,(C1-4)烷氧甲基或卤素;R4代表(C1-4)烷基;R5代表氢或(C1-4)烷基;R6代表氢或(C1-4)烷基。本发明还涉及该类化合物的药学上可接受的盐;以及将该类化合物用作药物,特别是促进睡眠的药物。
查看更多